Get in Touch
Writing About Blog Contact Get in Touch

One study, four readers

← Back to home
The Journal of Illustrative OncologyOriginal Article · 2026 · fictional

Drug X versus Standard Chemotherapy in Previously Treated Advanced Cancer

A. Example, B. Sample, C. Placeholder, et al.

Background
Options are limited after first-line treatment of advanced disease.
Methods
We randomly assigned 620 patients, in a 1:1 ratio, to receive Drug X or investigator’s choice of chemotherapy. The primary end point was progression-free survival; overall survival was a key secondary end point.
Results
Median progression-free survival was 9.2 months with Drug X and 5.6 months with chemotherapy (hazard ratio for progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.78; P<0.0001). The 12-month progression-free survival rate was 41% and 22%, respectively. Median overall survival was 27.0 months and 16.1 months (hazard ratio for death, 0.60; 95% CI, 0.47 to 0.77; P<0.0001); the 12-month overall survival rate was 74% and 60%. Adverse events of grade 3 or higher occurred in 52% and 38% of patients, respectively; the most common with Drug X were fatigue, diarrhoea and rash.
Conclusions
Drug X significantly prolonged progression-free and overall survival, with a higher rate of serious adverse events.
0612182430360255075100 Drug X Chemotherapy Hazard ratio for death, 0.60 (95% CI, 0.47–0.77) Months since randomisation Overall survival (%)
Figure 1. Kaplan–Meier estimates of overall survival (fictional data).

Clinical evidence summary · Oncology

Drug X extends overall survival by nearly 11 months after prior treatment, with more serious adverse events

A randomised phase III trial (fictional) of Drug X versus standard chemotherapy in 620 patients with previously treated advanced cancer.1

Key message. Median overall survival was 27.0 months with Drug X against 16.1 months with chemotherapy: a gain of 10.9 months and a 40% lower risk of death (HR 0.60). Progression-free survival was also longer; grade ≥3 adverse events were 14 percentage points more frequent.

How to read it

A hazard ratio of 0.60 means a 40% lower risk of death at any time during follow-up, and the confidence interval (0.47 to 0.77) lies clearly below 1.00. The benefit was already visible at one year, when 74% of patients on Drug X were alive, against 60%.

Limitations

Overall survival was a key secondary end point rather than the primary end point, and longer follow-up will refine the estimate. Serious adverse events, most often fatigue, diarrhoea and rash, need active monitoring and management.

Drug XChemotherapyChemoDifference
Median overall survival27.0 mo16.1 mo+10.9 moHR 0.60 (0.47–0.77)
Overall survival at 12 months74%60%+14 pp
Median progression-free survival9.2 mo5.6 mo+3.6 moHR 0.62 (0.49–0.78)
Grade ≥3 adverse events52%38%+14 pp

mo = months; pp = percentage points; HR = hazard ratio (95% confidence interval).

For practice

Drug X is an option to discuss with eligible patients after prior treatment. Set expectations about serious adverse events, and plan monitoring before starting.

1 Example A, Sample B, Placeholder C, et al. J Illustr Oncol 2026. Fictional trial created for illustration.

Scientific narrative · for scientific exchange, non-promotional

Drug X after first-line treatment: the need, the rationale and the evidence

The need

For patients whose cancer has progressed after first-line treatment, chemotherapy remains the usual next step, but its benefit is modest and short-lived. Clinicians are asking what else can give these patients more time.

The rationale

Drug X was designed to block a signalling pathway that drives growth in these tumours, a different mechanism from chemotherapy. The trial tested whether acting on that pathway would delay progression and, ultimately, extend life.1

What the trial showed

Median progression-free survival was 9.2 against 5.6 months, a 38% lower risk of progression or death. Median overall survival was 27.0 against 16.1 months, a 40% lower risk of death. At one year, 74% of patients on Drug X were alive, against 60%.

The open questions

The benefit comes with more serious adverse events (52% against 38%), mainly fatigue, diarrhoea and rash. Questions that remain are how durable the benefit is with longer follow-up, and which patients gain most. Present both the benefit and the burden with equal clarity.

In the conversation

Expect questions on tolerability, on which patients were studied and on how the survival result will mature. Answer from the data, within the studied population and the approved use, and offer the full publication.

1 Example A, Sample B, Placeholder C, et al. J Illustr Oncol 2026. Fictional trial created for illustration.

Patient information · fictional example

A new treatment option after your first treatment: what the Drug X study found

If your cancer has come back or grown after your first treatment, you may be wondering what comes next. Here is what a large study found.

What the study looked at

620 people whose cancer had grown after their first treatment took part. By chance, half were given Drug X and half were given chemotherapy. The researchers then followed them to see how they got on.

What it found

You may live longer. After one year, 74 out of every 100 people who took Drug X were still alive, compared with 60 out of every 100 who had chemotherapy. On average, people on Drug X lived for about 27 months, compared with about 16 months on chemotherapy.

Your cancer may stay under control for longer: about 9 months on average with Drug X, compared with about 5½ months with chemotherapy.

“On average” means the middle result across everyone in the study; your own experience may be different.

Side effects you should know about

Drug X can cause more serious side effects than chemotherapy. The most common were tiredness, diarrhoea and a skin rash. Tell your cancer team as soon as you notice any of these, because they can often help.

Questions you may want to ask your cancer team

  • Is Drug X suitable for me?
  • Which side effects am I most likely to have, and what can be done about them?
  • What would we do if the side effects became too hard to cope with?

AimThe source: a structured abstract, as published. Everything else is written from this.

Fictional trial and data, created for illustration.

Let’s talk

Get in Touch